The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
A phase 1b/2 study added the investigational BCL-2 inhibitor lisaftoclax to pomalidomide/dexamethasone (Pd) and daratumumab/lenalidomide/dexamethasone (DRd) regimens and observed improved outcomes in patients
A study presented by Saad Usmani, MD, MBA, of the Memorial Sloan Kettering Cancer Center, as part of the SOHO 2025 Annual Meeting,
Results from the phase 1/2 CA057-003 study showed early efficacy and safety with the addition of mezigdomide to novel combinations for relapsed or
The phase 3 MagnetisMM-6 study showed a manageable safety profile and high response rates in transplant-ineligible, newly diagnosed multiple myeloma (MM) patients treated
Ongoing results from the DREAMM-8 trial reinforced the clinically meaningful progression-free survival (PFS) benefit of belantamab mafodotin, pomalidomide, and dexamethasone (BPd) versus pomalidomide,
The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone (D-VRd) improved outcomes in patients with newly diagnosed multiple myeloma (MM) compared with VRd
A study presented by Meletios Dimopoulos, MD, of the National and Kapodistrian University of Athens, as part of the SOHO 2025 Annual Meeting,
A phase 1/2 study showed that iberdomide, daratumumab, and dexamethasone (IBERDd) had a manageable safety profile when used in transplant-ineligible, newly diagnosed multiple
Prior studies have shown conflicting outcomes for patients with different follicular lymphoma (FL) grade subtypes. A recent study by Patrizia Mondello, MD, PhD
